Stockscreener 앱 받기
187.03
1.43%
-2.72
Astrazeneca Plc 주식(AZN)의 최신 뉴스
AstraZeneca Maintains FTSE Presence Through Oncology and Global Healthcare - Kalkine Media
AstraZeneca, Daiichi Sankyo’s Datroway receives FDA approval for TNBC - Pharmaceutical Technology
AstraZeneca stock (US6549022043): New drug and earnings updates keep investors focused - AD HOC NEWS
Why Are Rolls-Royce and AstraZeneca Trending - Kalkine Media
Why is AstraZeneca attracting healthcare discussion across the United Kingdom market? - Kalkine Media
AstraZeneca Expands Healthcare Presence Across FTSE 100 Pharmaceutical - Kalkine Media
AstraZeneca: 8% Q1 Revenue Growth And Imfinzi/Ultomiris Trial Data Wins - Seeking Alpha
AstraZeneca plc stock (GB0009895292): FDA approvals and oncology pipeline keep investors watching - AD HOC NEWS
AstraZeneca PLC stock (US6549022043): FDA decisions and oncology pipeline keep investors alert - AD HOC NEWS
AstraZeneca Plc (LSE:AZN) Share Price, History, & News - twelfthmagpie.com
AstraZeneca wins FDA AdCom backing for Truqap in prostate cancer - MSN
AstraZeneca PLC stock (US6549022043): insider sale and oncology spotlight draw investor attention - AD HOC NEWS
Insider Sell: Mani Sharma Sells Shares of AstraZeneca PLC - GuruFocus
XXI WEALTH, LLC's AstraZeneca PLC(AZN) Holding History - GuruFocus
AstraZeneca (AZN) officer Sharma Mani sells 11,893 Ordinary Shares in open market - Stock Titan
FTSE 100 Closes Week Upbeat; AstraZeneca Sees Oncology Approval Progress - Yahoo Finance UK
EU regulator backs approval for AstraZeneca's experimental breast cancer pill - Reuters
AstraZeneca and Daiichi cancer drugs clear regulatory hurdles - London South East
AstraZeneca PLC stock (US6549022043): oncology growth and new approvals keep investors watching - AD HOC NEWS
Datroway approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates - AstraZeneca
Enhertu recommended for approval in the EU by CHMP for patients with previously treated HER2-positive metastatic solid tumours - AstraZeneca
CT UK Capital underperforms as underweight on AstraZeneca, Shell - marketscreener.com
AZN News | ASTRAZENECA PLC (NYSE:AZN) - ChartMill
AstraZeneca plc stock (GB0009895292): Deutsche Bank reiterates Sell despite strong analyst consensus - AD HOC NEWS
AZN Stock Quote Price and Forecast - CNN
AstraZeneca plc stock (GB0009895292): Deutsche Bank reiterates Sell rating as pipeline and US listin - AD HOC NEWS
AstraZeneca PLC stock (US6549022043): analysts update views as pipeline news keeps investors alert - AD HOC NEWS
ASTRAZENECA : Deutsche Bank reiterates its Sell rating - marketscreener.com
AstraZeneca stock holds steady after net debt rises £2.5 billion following dividend payment - Traders Union
AZN Technical Analysis | Trend, Signals & Chart Patterns | ASTRAZENECA PLC (NYSE:AZN) - ChartMill
Research Alert: CFRA Adds Shares Of Astrazeneca Plc To The Total Return Portfolio - 富途牛牛
How VEPPANU Approval Frames Expectations For AstraZeneca’s Camizestrant In ESR1 Disease - Yahoo Finance
AstraZeneca plc stock (GB0009895292): Latest catalyst after recent company news - AD HOC NEWS
ESR1-Mutated Metastatic Breast Cancer Market Expected to Grow Rapidly at 9.6% CAGR During the Forecast Period (2026–2036) Due to the Emergence of Novel Oral SERDs and Targeted Agents | DelveInsight - GlobeNewswire Inc.
AstraZeneca PLC stock (US6549022043): US drug approvals keep Big Pharma name in focus - AD HOC NEWS
AZN Stock Price and Chart — LSE:AZN - TradingView
AstraZeneca’s Earnings Call Balances Growth and Risk - TipRanks
AstraZeneca plc stock (GB0009895292): oncology momentum and new data keep investors watching - AD HOC NEWS
AstraZeneca plc stock (GB0009895292): US drug approvals keep pharma giant in focus - AD HOC NEWS
AstraZeneca stock (GB0009895292): lung cancer data and Q1 update keep focus on oncology pipeline - AD HOC NEWS
AstraZeneca PLC stock (US6549022043): US drug approvals and oncology milestone keep pipeline in focu - AD HOC NEWS
FDA approves AstraZeneca’s new kind of hypertension drug - BioPharma Dive
Flat trading for AstraZeneca stock as GBX13,902 resistance keeps gains in check - Traders Union
AstraZeneca plc stock (GB0009895292): US drug approvals trigger milestone payment and fresh attentio - AD HOC NEWS
AstraZeneca’s New FDA Wins Raise Questions On Growth And Valuation - Yahoo Finance
AstraZeneca Scores Key FDA Wins Across Cardiovascular And Oncology PortfoliosAstraZeneca (NYSE:AZN) - Benzinga
New hypertension option as Astrazeneca’s Baxfendy wins FDA nod - BioWorld News
AstraZeneca Gets FDA Nod for New Hypertension Drug Baxfendy - Yahoo! Finance Canada
AstraZeneca CEO Pascal Soriot receives vested share award under performance plan - Investing.com
AstraZeneca (AZN) CEO granted 18,359 shares as performance award vests - Stock Titan
AstraZeneca receives US approval for Baxfendy to treat hypertension By Investing.com - Investing.com Nigeria
AstraZeneca receives US approval for Baxfendy to treat hypertension - Investing.com
AstraZeneca plc stock (GB0009895292): oncology and vaccines stay in focus after latest earnings and - AD HOC NEWS
AstraZeneca (AZN) secures US approval for first-in-class Baxfendy hypertension treatment - Stock Titan
Enhertu gains early breast cancer approvals for AstraZeneca (NYSE: AZN) in US - Stock Titan
The Zacks Analyst Blog Highlights Costco, Coca-Cola, AstraZeneca and Franklin Financial Services - Yahoo Finance
Citi sees buying opportunity at AstraZeneca after recent falls - Sharecast.com
New AstraZeneca drug targets hormone behind stubborn high blood pressure - Stock Titan
AstraZeneca wins US FDA approval for hypertension drug Baxfendy - MSN
AstraZeneca Announce Baxfendy Approval in the US May 18, 2026 - James Sharp & Co.
US regulator greenlights AstraZeneca's blood pressure drug Baxfendy - London South East
AstraZeneca secures US approval for two drugs - Sharecast.com
AstraZeneca stock holds steady as Enhertu FDA approval for early breast cancer balances sentiment - Traders Union
0.16%
자본화:
|
볼륨(24시간):